Good MorningEquity markets were mostly flat on Monday but pulled back nearly 1.0% last in the day as traders brace for another round of economic data. The list kicks off today with a read of the PPi and it should be another hot one at 0.4% month to month. If so, it will underpin the idea that consumer-level inflation is yet to cool off despite the recently weakened CPI report. Also on tap, this week is Retail Sales and the Index of Leading Indicators, which the market often overlooks.
In other news, the New York Fed's inflation gauge shows the expectations for short and long-running inflation have increased. This could lead the FOMC to act aggressively at the next meeting although some members have indicated it may be appropriate to slow the pace of hikes soon. The takeaway is that inflation is still hot, the data is still iffy, and the FOMC is on track to hike rates above 5.0% by early 2023. With interest rates on the rise and the outlook for earnings in decline, the rally in the S&P 500 may not get far if it's not already over. Featured: Most of 2026's IPO class failed this test (Ad) 
|
Consumer Discretionary | |
The days of pandemic-fueled profits and $300 share prices are a distant memory for Wayfair Inc. (NYSE: W). Things were bound to normalize for the online home goods retailer, but its fall from grace has been one of the most stunning post-Covid plunges yet.
The reality check back to 2014 IPO levels... Read the Full Story |
|
From Our Partners | | A new tool called Oracle tracks insider bets hidden in the predictions market, flagging which stocks and options could be affected.
During beta testing, Oracle identified notable short-term moves including USO up 39% in four days, PLTR up 43% in a day, and WEN up 67% in two days, all through a regular brokerage account.
See how Oracle spots these hidden insider bets before they make headlines. | | Get free access to Oracle and see the data now |
|
Technology | |
Very few technology stocks are trading at 10-year highs, but San Jose-based Sanmina Corporation (NASDAQ: SANM) is one of them.
Last week, the mid-cap gapped up after another strong quarterly report. It put a bow on what was a phenomenal fiscal 2022 for the company. Earnings per share (EPS) handi... Read the Full Story |
|
Consumer Discretionary | |
The Chinese electric vehicle (EV) manufacturer NIO (NYSE: NIO) released its unaudited third-quarter results for 2022 on November 10, which reported mixed developments for the company.
Although NIO recorded record-high vehicle deliveries and significant top-line revenue growth, its net loss swe... Read the Full Story |
|
From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
|
Communication Services | | Video game developer and publisher Take-Two Interactive Software (NASDAQ: TTWO) stock got pummeled on its recent fiscal Q2 2023 earnings report. Losses were larger than expected with 70% attributed to the weakness in its mobile business and $50 million in FX headwinds as it collects 40% of net reven... Read the Full Story |
|
Industrials | |
If you are interested in Joby Aviation (NYSE: JOBY) it may be time to get on board for the ride of a lifetime. The company is one of the most innovative EV company’s on the market and it is in production which is the primary component of a successful EV investment. For those that don’t... Read the Full Story |
|
|
Markets | |
Last fall, Catalent, Inc. (NYSE: CTLT) climbed to a record high above $140 on rising demand for biologics and drug delivery technologies. Since then, fall is all it has done.
The latest plunge on November 1st was a high volume gapper that followed the company’s fiscal first quarter earnings... Read the Full Story |
|
Consumer Staples | |
Tyson Foods (NYSE: TSN) has been quietly trending lower on fears of inflation, slowing sales and reduced profitability but that has the stock at levels that may be too cheap to ignore. The stock is trading at only 7.75X its 2023 adjusted EPS guidance and the odds for outperformance are high. Relat... Read the Full Story |
|
Communication Services | | Social media technology provider Alphabet (NASDAQ: GOOG) stock is down (-33%) for the year after rallying 11% off its earnings lows. As complicated as Alphabet and its numerous side ventures can be, it is really just a massive advertising platform powered by the world’s most active search engi... Read the Full Story |
|
Communication Services | | Media and entertainment giant The Walt Disney Company (NYSE: DIS) stock has seen better days as shares cratered under the $90.71 double bottom on its weak Q4 2022 earnings release. Since the pandemic, Disney has been identified as a video streaming company and judged by its subscription base for Dis... Read the Full Story |
|
Technology | | Shares of solar battery system maker Enphase Energy (NASDAQ: ENPH) briefly cleared a buy point Friday, but reversed lower, even as the broader market advanced.
That type of price action happens fairly often, as investors who bought at certain levels nab profits as the stock overcomes price resistan... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
